Mylan NV (MYL)

29.05
NASDAQ : Health Technology
Prev Close 30.04
Day Low/High 28.96 / 29.96
52 Wk Low/High 28.96 / 47.82
Avg Volume 5.03M
Exchange NASDAQ
Shares Outstanding 515.63M
Market Cap 15.68B
EPS 1.30
P/E Ratio 28.88
Div & Yield N.A. (N.A)

Latest News

Mylan Expands Gastroenterology Portfolio With Launch Of Generic For Prevacid® SoluTab Delayed-Release Orally Disintegrating Tablets

Mylan Expands Gastroenterology Portfolio With Launch Of Generic For Prevacid® SoluTab Delayed-Release Orally Disintegrating Tablets

Mylan's Lansoprazole Delayed-Release Orally Disintegrating Tablets are approved to treat certain types of gastrointestinal ulcers

Mylan To Present At Nasdaq's 39th London Investor Conference

Mylan To Present At Nasdaq's 39th London Investor Conference

HERTFORDSHIRE, England and PITTSBURGH, Nov. 26, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

Heat Biologics Inc. nosedived after the Durham, North Carolina-based biopharmaceutical company filed for a share offering pricing expected to hit $12 million.

Mylan Statement In Response To FDA Warning Letter Relating To Morgantown Plant

Mylan Statement In Response To FDA Warning Letter Relating To Morgantown Plant

HERTFORDSHIRE, England and PITTSBURGH, Nov. 20, 2018 /PRNewswire/ --  Mylan N.

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Shares of the New York City-based pharmaceutical giant are rising on Monday.

Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'

Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'

Let's check of the charts and indicators to see if this is a good time to approach the long side of MYL.

Fab Five FAANG Stocks: Cramer's 'Mad Money' Recap (Tuesday 11/13/18)

Fab Five FAANG Stocks: Cramer's 'Mad Money' Recap (Tuesday 11/13/18)

Jim Cramer's got a different perspective on the recent performance of the companies we love to hate: Facebook, Amazon, Apple, Netflix, Google.

Dropbox, Teva Pharmaceuticals, Salesforce: 'Mad Money' Lightning Round

Dropbox, Teva Pharmaceuticals, Salesforce: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Dropbox, Teva Pharmaceuticals, Salesforce, Linde, iQiyi and more.

Theravance Biopharma And Mylan Receive FDA Approval For YUPELRI™ (revefenacin) In Adults With Chronic Obstructive Pulmonary Disease

Theravance Biopharma And Mylan Receive FDA Approval For YUPELRI™ (revefenacin) In Adults With Chronic Obstructive Pulmonary Disease

YUPELRI (revefenacin) is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US

Mylan Moves Up In Analyst Rankings, Passing TechnipFMC

Mylan Moves Up In Analyst Rankings, Passing TechnipFMC

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Mylan NV has taken over the #180 spot from TechnipFMC plc , according to ETF Channel. Below is a chart of Mylan NV versus TechnipFMC plc plotting their respective rank within the S&P 500 over time (MYL plotted in blue; FTI plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Mylan Shares Soar After Drugmaker's Earnings Top Forecasts

Mylan Shares Soar After Drugmaker's Earnings Top Forecasts

Shares of generic drugmaker Mylan soar after adjusted earnings top analysts' forecasts.

Mylan Reports Third Quarter 2018 Results And Reaffirms 2018 Guidance

Mylan Reports Third Quarter 2018 Results And Reaffirms 2018 Guidance

HERTFORDSHIRE, England and PITTSBURGH, Nov. 5, 2018 /PRNewswire/ -- Mylan N.

Amazon, Warren Buffett and 'Bohemian Rhapsody' - 5 Things You Must Know

Amazon, Warren Buffett and 'Bohemian Rhapsody' - 5 Things You Must Know

U.S. stock futures are lower on Monday, as stronger-than-expected U.S. jobs data reignites bets on faster Federal Reserve rate hikes and as investors look ahead to the midterm elections on Tuesday; Amazon reportedly has held advanced talks about establishing its second headquarters in Crystal City, Virginia; 'Bohemian Rhapsody' makes $50 million in its opening weekend.

4 Scenarios That Will Impact the Market: Market Recon

4 Scenarios That Will Impact the Market: Market Recon

And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.

Mylan Launches Hulio™ (Biosimilar Adalimumab) In Markets Across Europe

Mylan Launches Hulio™ (Biosimilar Adalimumab) In Markets Across Europe

HERTFORDSHIRE, England and PITTSBURGH, Oct. 19, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan And Biocon Announce Positive CHMP Opinion For Ogivri®, Biosimilar Trastuzumab

Mylan And Biocon Announce Positive CHMP Opinion For Ogivri®, Biosimilar Trastuzumab

HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Oct. 19, 2018 /PRNewswire/ --  Mylan N.

Mylan Adds To Women's Healthcare Portfolio With Launch Of Generic Depo-Provera® Injection

Mylan Adds To Women's Healthcare Portfolio With Launch Of Generic Depo-Provera® Injection

- Mylan's Medroxyprogesterone Acetate Injection is indicated for the prevention of pregnancy-

Mylan To Release Third Quarter 2018 Financial Results On November 5, 2018

Mylan To Release Third Quarter 2018 Financial Results On November 5, 2018

HERTFORDSHIRE, England and PITTSBURGH, Oct. 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan Prevails In Copaxone® 40mg/mL Litigation Against Teva In U.S. Appellate Court

Mylan Prevails In Copaxone® 40mg/mL Litigation Against Teva In U.S. Appellate Court

Court Affirms Prior Decisions Finding Copaxone® 40 mg/mL Patents Invalid

Theravance Biopharma And Mylan Report Positive New Data From Multiple Studies Of YUPELRI™ (revefenacin) At The 2018 CHEST Annual Meeting

Theravance Biopharma And Mylan Report Positive New Data From Multiple Studies Of YUPELRI™ (revefenacin) At The 2018 CHEST Annual Meeting

Additional Analyses of Phase 3 Program Data Highlight Efficacy Advantages for 175 mcg/day of YUPELRI in Key Patient Subgroups, Demonstrate Acceptable Cardiovascular Safety Profile

Theravance Biopharma And Mylan To Present New Data From Studies Of YUPELRI™ (revefenacin) At The 2018 CHEST Annual Meeting

Theravance Biopharma And Mylan To Present New Data From Studies Of YUPELRI™ (revefenacin) At The 2018 CHEST Annual Meeting

Presentations Highlight Data of YUPELRI Compared with Tiotropium in Subpopulation of COPD Patients with Suboptimal Peak Inspiratory Flow Rates, Report Additional Data from Pivotal Phase 3 Program in Patients with Moderate to Very Severe COPD

3 Small Biotech Stocks to Watch in the Fourth Quarter

3 Small Biotech Stocks to Watch in the Fourth Quarter

These are just a few of the names I expect to do well to close out 2018.

3 Small Biotechs on My Q4 Watch List

3 Small Biotechs on My Q4 Watch List

These are a few of the names I expect to do well to close out 2018.

Mylan Extends Commitment To Fight HIV/AIDS By Partnering With Atomo Diagnostics To Expand Access To HIV Self-Testing In Low- And Middle-Income Countries

Mylan Extends Commitment To Fight HIV/AIDS By Partnering With Atomo Diagnostics To Expand Access To HIV Self-Testing In Low- And Middle-Income Countries

HERTFORDSHIRE,  England and PITTSBURGH and SYDNEY, Sept. 24, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan And Biocon Announce Positive CHMP Opinion For Fulphila®, Biosimilar Pegfilgrastim

Mylan And Biocon Announce Positive CHMP Opinion For Fulphila®, Biosimilar Pegfilgrastim

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Sept. 21, 2018 /PRNewswire/ --   Mylan N.

Mylan Launches Authorized Generic Of Ampyra® Tablets

Mylan Launches Authorized Generic Of Ampyra® Tablets

- Mylan's Dalfampridine Extended-Release Tablets, 10 mg, are indicated for patients with multiple sclerosis -

Mylan And Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization For Hulio®, Biosimilar Adalimumab

Mylan And Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization For Hulio®, Biosimilar Adalimumab

HERTFORDSHIRE, England and PITTSBURGH and TOKYO, Sept. 20, 2018 /PRNewswire/ --  Mylan N.

TheStreet Quant Rating: C (Hold)